Non-small cell lung cancer Pipeline

Mar 28, 2025

Non-small cell lung cancer (NSCLC) remains one of the toughest cancers to treat, but bispecific antibodies (BsAbs) are changing the game. Unlike traditional therapies, BsAbs are engineered to target two different antigens simultaneously, enhancing precision and boosting immune response. This dual-targeting approach...

Nov 29, 2024

Non-small cell lung cancer (NSCLC) is the most common cancer, accounting for approximately 85% of the total lung cancers in the United States. Almost 500K cases in the 7MM were diagnosed in 2022 alone. Moreover, significant deaths were recorded at the end of the same year. Analysis indicates that the most common ge...

Nov 29, 2024

Lung cancer, to date, remains the leading cause of death worldwide, however, the epidemiological analysis depicts varying NSCLC incidence all over the world. In 2022, there were an estimated 20 million new cancer cases and 9.7 million cancer-related deaths. The number of people living for at least five years after ...

Nov 29, 2024

The treatment options for  Non-Small Cell Lung Cancer (NSCLC) have been flooded in recent years due to improved methods of molecular profiling and better diagnostic tools. The new molecular biomarkers, with their efficacious treatments for NSCLC, have changed the lives of patients where the clinical prognosis was v...

Nov 29, 2024

According to the World Health Organization (WHO), in 2022, there were approximately 2.5 million new cases of lung cancer globally, which accounted for 12.4% of all newly diagnosed cancer cases. Lung cancer continues to be one of the most common and deadly malignancies worldwide, with significant contributions to gl...

Nov 06, 2019

The Non-small cell lung cancer therapeutics market is anticipated to improve owing to better diagnostics methodologies and treatment options across the world. This would expand the NSCLC market size enabling the drug manufacturers to penetrate more into the market. Companies across the globe are diligently working ...

Aug 23, 2019

The drug Imfinzi (durvalumab) has failed to come up as an effective treatment option for treating non-small cell lung cancer (NSCLC). The result of the NEPTUNE study was not much of a promising one and has been disclosed completely. The Pharma giant, AstraZeneca, has announced the incompetence of its lead candidate...